Browse our 650+ Publications
Latest Publications
Lisocabtagene Maraleucel for Richter’s Transformation—A Case Series
Smith C, et al.
eJHaem
March 2025
Authors and Affiliates
Courtney J. Smith1 Anmol Goyal1 Brian R. Smith1 Dasom Lee2 Alexandria Jensen3 Jonathan Alexander1
Melody Smith1 Matthew Frank1 Saurabh Dahiya1 David Miklos1 Sushma Bharadwaj1
1Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA 2Division of
Hematology, Stanford University School of Medicine, Stanford, California, USA 3Quantitative Sciences Unit, Stanford University School of Medicine, Stanford,
California, USA
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
Facon T, et al.
Leukemia
February 2025
Authors and Affiliates
Thierry Facon1, Philippe Moreau 2, Katja Weisel 3, Hartmut Goldschmidt 4, Saad Z. Usmani 5, Ajai Chari6, Torben Plesner7,
Robert Z. Orlowski 8, Nizar Bahlis 9, Supratik Basu 10, Cyrille Hulin 11, Hang Quach 12, Michael O’Dwyer 13,
Aurore Perrot 14, Caroline Jacquet15, Christopher P. Venner16,17, Noopur Raje18, Mourad Tiab19, Margaret Macro20, Laurent Frenzel21,
Xavier Leleu 22, Gordon Cook 23, George Wang24, Huiling Pei25, Maria Krevvata24, Robin Carson24, Fredrik Borgsten26 and
Shaji K. Kumar
1University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France. 2Hematology Department, University Hospital Hôtel-Dieu, Nantes, France. 3Department of Oncology,
Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4GMMG-Study Group at
University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany. 5Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6Icahn School of Medicine at Mount
Sinai, New York, NY, USA. 7Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 8Department of Lymphoma & Myeloma, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA. 9Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. 10Royal Wolverhampton NHS Trust and University of
Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, UK. 11Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France. 12University of
Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia. 13Department of Medicine/Haematology, NUI, Galway, Republic of Ireland. 14CHU de Toulouse, IUCT-O, Université de
Toulouse, UPS, Service d’Hématologie, Toulouse, France. 15Department of Hematology, University Hospital, Nancy, France. 16Department of Medical Oncology, Cross Cancer
Institute, University of Alberta, Edmonton, AB, Canada. 17BC Cancer – Vancouver Centre Group, Vancouver, BC, Canada. 18Center for Multiple Myeloma, Massachusetts General
Hospital Cancer Center, Boston, MA, USA. 19CHD Vendée, La Roche sur Yon, France. 20Centre Hospitalier Universitaire (CHU) de Caen, Caen, France. 21Hôpital Necker-Enfants
Malades, Paris, France. 22CHU Poitiers, Hôpital la Milétrie, Poitiers, France. 23Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds,
Leeds, UK. 24Janssen Research & Development, LLC, Spring House, PA, USA. 25Janssen Research & Development, LLC, Titusville, NJ, USA. 26Janssen Research & Development, LLC,
Raritan, NJ, USA. 27Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients with Comparable Rates of Minimal Residual Disease Negativity
Kort J, et al.
Clinical Lymphoma Myeloma & Leukemia
February 2025
Authors and Affiliates
Jeries Korta,b,1, Nikolas Naleidc
, Frank Oleya
, James Ignatz-Hoovera,b, Seunghee
Margeviciusd
, Pingfu Fud
, Ehsan Maleka,b,2, Brenda Coopera,b
a. Department of Hematology and Oncology, University Hospitals Seidman Cancer Center,
Cleveland, OH
b. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
c. Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH
d. Case Western Reserve University, Department of Population and Quantitative Health
Sciences, Cleveland, OH
1. University of Kansas Medical Center, Kansas City, KS
2. Roswell Park Cancer Institute, Buffalo, NY
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Shi Q, et al.
J Clin Oncol
February 2025
Authors and Affiliates
Qian Shi, PhD1 ; Bruno Paiva, PhD2 ; Levi D. Pederson, MS1 ; Natalie Dimier, PhD3; Ela Talpes, PhD4; Thomas J. Prior, PhD5 ;
Alberto Orfao, MD, PhD6 ; Philippe Moreau, MD, PhD7 ; Pieter Sonneveld, MD, PhD8 ; Shaji K. Kumar, MD9 ; Jesse G. Dixon, MS1;
Reshma Patel, PhD10; Blake J. Bartlett, PhD5; Jordan Schecter, MD5; Phillip McCarthy, MD11 ; Dirk Hose, MD12 ; Anja Seckinger, MD12 ;
D’Agostino Mattia, MD13 ; Hartmut Goldschmidt, MD14 ; Stefania Oliva, MD15 ; Roger G. Owen, MD16; Kenneth C. Anderson, MD17 ;
Jes´us San-Miguel, MD, PhD18 ; Brian G.M. Durie, MD19; and Nikhil Munshi, MD17 ; on behalf of the International Independent Team for Endpoint
Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group
1Department of Quantitative Health Sciences, Mayo Clinic, Rochester,
MN
2Department of Hematology and Immunology, University of Navara,
Pamplona, Spain
3Roche Products Limited, St Albans, United Kingdom
4Amgen Inc, San Francisco, CA
5Johnson & Johnson Inc, New Brunswick, NJ
6Department of Medicine, University of Salamanca, Salamanca, Spain
7Hematology Department, University Hospital Hotel-dieu, Nantes,
France
8Department of Hematology, Erasmus MC Cancer Institute, Rotterdam,
the Netherlands
9Division of Hematology, Mayo Clinic, Rochester, MN
10Johnson & Johnson Inc, High Wycombe, United Kingdom
11Roswell Park Cancer Institute, Buffalo, NY
12Department of Hematology and Immunology, Myeloma Center
Brussels & Labor f¨ur Myelomforschung, Vrije Universiteit Brussel (VUB),
Jette, Belgium
13Division of Hematology, Department of Molecular Biotechnology and
Health Sciences, AOU Citt `a della Salute e della Scienza di Torino,
University of Torino, Torino, Italy
14University Hospital Heidelberg, GMMG—Study Group at the University
Hospital Heidelberg, Heidelberg, Germany
15Myeloma Unit, Division of Hematology, University of Torino, Turin,
Italy
16St James Institute, Leeds, United Kingdom
17Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
18Professor of Hematology, Senior Consultant & Strategic Advisor,
Clinica Universidad de Navarra, Pamplona, Spain
19Cedars Sinai Outpatient Cancer Center, Los Angeles, CA
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
Usmani S, et al.
Nature Medicine
February 2025
Authors and Affiliates
Saad Z. Usmani 1 , Thierry Facon2, Vania Hungria3, Nizar J. Bahlis 4, Christopher P. Venner5,6, Marc Braunstein7,
Ludek Pour8, Josep M. Martí9, Supratik Basu 10, Yael C. Cohen 11,12, Morio Matsumoto13, Kenshi Suzuki14, Cyrille Hulin15,
Sebastian Grosicki16, Wojciech Legiec17, Meral Beksac18, Angelo Maiolino 19,20, Hiroyuki Takamatsu21, Aurore Perrot 22,
Mehmet Turgut23, Tahamtan Ahmadi24, Weiping Liu25, Jianping Wang26, Katherine Chastain27, Jessica Vermeulen28,
Maria Krevvata26, Lorena Lopez-Masi27, Jodi Carey26, Melissa Rowe29, Robin Carson26 & Sonja Zweegman30
1Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France.
3Clínica Médica São Germano, São Paulo, Brazil. 4Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
5Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. 6BC Cancer—Vancouver Centre, University
of British Columbia, Vancouver, British Columbia, Canada. 7Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA. 8University Hospital Brno,
Brno, Czech Republic. 9Hospital Universitario Mútua de Terrassa, Terrassa, Spain. 10Royal Wolverhampton NHS Trust and University of Wolverhampton,
CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK. 11Department of Hematology, Tel Aviv Sourasky (Ichilov)
Medical Center, Tel Aviv, Israel. 12Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. 13Department of Hematology, National
Hospital Organization Shibukawa Medical Center, Gunma, Japan. 14Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
15Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France. 16Department of Hematology and Cancer Prevention, School of
Public Health, Medical University of Silesia, Katowice, Poland. 17Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology
Center of Lublin Land, Lublin, Poland. 18Istinye University, Ankara Liv Hospital, Ankara, Turkey. 19Instituto Americas de Ensino, Pesquisa e Inovação, Rio
de Janeiro, Brazil. 20Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 21Department of Hematology, Kanazawa University Hospital, Kanazawa
University, Kanazawa, Japan. 22CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France. 23Department of
Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey. 24Genmab US, Inc., Plainsboro, NJ, USA. 25Johnson & Johnson, Shanghai,
China. 26Johnson & Johnson, Spring House, PA, USA. 27Johnson & Johnson, Raritan, NJ, USA. 28Johnson & Johnson, Leiden, The Netherlands. 29Johnson &
Johnson, High Wycombe, UK. 30Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam,
The Netherlands.
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
Costa L, et al.
Blood Cancer Journal
February 2025
Authors and Affiliates
Luciano J. Costa 1✉, Eva Medvedova2, Binod Dhakal 3,
Bhagirathbhai R. Dholaria 4, Kelly N. Godby1, Susan Bal1,
Gayathri Ravi1, Smith Giri1, Saurabh Chhabra 3,5,
Rebecca Silbermann2 and Natalie S. Callander 6
1Division of Hematology/Oncology, University of Alabama at
Birmingham, Birmingham, AL, USA. 2Division of Hematology/
Oncology, Knight Cancer Institute, Oregon Health & Science
University, Portland, OR, USA. 3Division of Hematology/Oncology,
Department of Medicine, Medical College of Wisconsin, Milwaukee,
WI, USA. 4Department of Medicine, Division of Hematology &
Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
5Division of Hematology/Oncology, Department of Medicine, Mayo
Clinic, Phoenix, AZ, USA. 6University of Wisconsin, Madison, WI, USA.
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Brown J, et al.
nejm
February 2025
Authors and Affiliates
J.R. Brown,1 J.F. Seymour,2,3 W. Jurczak,4 A. Aw,5 M. Wach,6 A. Illes,7 A. Tedeschi,8
C. Owen,9 A. Skarbnik,10 D. Lysak,11 K.-S. Eom,12 M. Šimkovič,13 M.A. Pavlovsky,14
A.P. Kater,15 B. Eichhorst,16 K. Miller,17 V. Munugalavadla,17 T. Yu,17 M. de Borja,18
and P. Ghia,19,20 for the AMPLIFY investigators*
1 Dana–Farber Cancer Institute, Boston; 2 Peter MacCallum
Cancer Centre, University of Melbourne, Melbourne, VIC, Australia;
3 Royal Melbourne Hospital, University of Melbourne,
Melbourne, VIC, Australia; 4 Maria Sklodowska-Curie National
Institute of Oncology, Kraków, Poland; 5 University of Ottawa,
Ottawa; 6 Medical University of Lublin, Lublin, Poland; 7 Faculty
of Medicine, Division of Hematology, Department of Internal
Medicine, University of Debrecen, Debrecen, Hungary; 8 ASST
Grande Ospedale Metropolitano Niguarda, Niguarda Cancer
Center, Milan; 9 University of Calgary, Calgary, AB, Canada;
10 Novant Health Cancer Institute, Charlotte, NC; 11 Fakultní Nemocnice
Plzen, Pilsen, Czech Republic; 12 Catholic Hematology
Hospital, Seoul St. Mary’s Hospital, College of Medicine, the
Catholic University of Korea, Seoul, South Korea; 13 4th Department
of Internal Medicine–Hematology, Faculty of Medicine in
Hradec Králové, University Hospital and Charles University,
Hradec Kralove, Czech Republic; 14 FUNDALEU, Clinical Research
Center, Buenos Aires; 15 Amsterdam University Medical
Centers, University of Amsterdam, Amsterdam; 16 University
Hospital Cologne, Cologne, Germany; 17 AstraZeneca, South
San Francisco, CA; 18 AstraZeneca, Mississauga, ON, Canada;
19 Università Vita-Salute San Raffaele, Milan; 20 IRCCS Ospedale
San Raffaele, Milan.
Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
Perrot A, et al.
Blood
January 2025
Authors and Affiliates
Aurore Perrot,1 Cyrille Touzeau,2 Jerome Lambert,3 Cyrille Hulin,4 Denis Caillot,5 Lionel Karlin,6 Bertrand Arnulf,7
Philippe Rey,8 Laurent Garderet,9 Margaret Macro,10 Martine Escoffre Barbe,11 Julie Gay,12 Thomas Chalopin,13
Romain Gounot,14 Jean-Marc Schiano,15 Mourad Tiab,16 Mohamad Mohty,17 Frederique Kuhnowski,18 Jean
Fontan,19 Salomon Manier,20 Frederique Orsini-Piocelle,21 Laure Vincent,22 Sophie Rigaudeau,23 Xavier Leleu,24
Benjamin Hebraud,1 Laurent Flet,25 Jean-Valere Malfuson,26 Caroline Jacquet,27 Driss Chaoui,28 Nathalie
Meuleman,29 Wajed Abarah,30 Lydia Montes,31 Riad Benramdane,32 Cecile Sonntag,33 Hacene Zerazhi,34 Alina
Danu,35 Olivier Allangba,36 Mamoun Dib,37 Murielle Roussel,38 Sophie Cereja,39 Julien Depaus,40 Nicolas
Branche,41 Helene Demarquette,42 Valentine Richez,43 Brieuc Cherel,44 Laurent Frenzel,45 Marie-Christiane
Vekemans,46 Noemie Bigot,3 Herve Avet-Loiseau,47 Jill Corre,47 Philippe Moreau2
1Hematologie, Hopital Universitaire de Toulouse, France
2Hematologie, Hopital Universitaire de Nantes, France
3Biostatistique, Hopital Universitaire Saint Louis, APHP, Paris, France
4Hematologie, Hopital Universitaire de Bordeaux, France
5Hematologie, Hopital Universitaire de Dijon, France
6Hematologie, Hopital Universitaire de Lyon Sud, France
7Hematologie, Hopital Universitaire Saint Louis, APHP, Paris, France
8Hematologie, Centre Léon Bérard, Lyon, France
9Hematologie, Hopital Universitaires Pitié Salpêtrière, APHP, Paris, France
10Hematologie, Hopital Universitaire de Caen, France
11Hematologie, Hopital Universitaire de Rennes, France
12Hematologie, Hopital de Bayonne, France
13Hematologie, Hopital Universitaire de Tours, France
14Hematologie, Hopital Universitaire Henri Mondor, Créteil, France
15Hematologie, Institut Paoli Calmettes, Marseille, France
16Hematologie, Hopital Vendée, La Roche sur Yon, France
17Hematologie, Hopital Universitaire Saint Antoine, APHP, Paris, France
18Hematologie, Institut Curie, Paris, France
19Hematologie, Hopital Universitaire de Besançon, France
20Hematologie, Hopital Universitaire de Lille, France
21Hematologie Hopital d’Annecy, France
22Hematologie, Hopital Universitaire de Montpellier, France
23Hematologie, Hopital de Versailles, France
24Hematologie, Hopital Universitaire de Poitiers, France
25Parmacie, Hopital Universitaire de Nantes, France
26Hematologie, Hopital d’Instruction des Armees, Percy, France
27Hematologie Hopital Universitaire de Nancy, France
28Hematologie, Hopital d’Argenteuil, France
29Hematologie, Institut Jules Bordet, Bruxelles, Belgique
30Hematologie, Grand Hopital de l’Est Francilien, Meaux, France
31Hematologie, Hopital Universitaire d’Amiens, France
32Hematologie Hopital de Cergy-Pontoise, France
33Hematologie, ICANS, Strasbourg, France
34Hematologie, Hopital d’Avignon, France
35Hematologie, Institut Gustave Roussy, Villejuif, France
36Hematologie, Hopital de Saint Brieuc, France
37Hematologie, Hopital Universitaire d’Angers, France
38Hematologie Hopital Universitaire de Limoges, France
39Hematologie, Hopital Sud Francilien, Corbeil Essonnes, France
40Hematologie, Hopital de Namur, Belgium
41Hematologie, Hopital Universitaire de Nîmes, France
42Hematologie, Hopital de Dunkerque, France
43Hematologie, Hopital Universitaire de Nice, France
44Hematologie, Hopital de Vannes, France
45Hematologie, Hopital Universitaire Necker, APHP, Paris, France
46Hematologie, Cliniques Universitaires St Luc, Bruxelles, Belgium
47Unite Genomique du Myelome, Toulouse, France
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Moreau P, et al.
Leukemia
January 2025
Authors and Affiliates
Philippe Moreau 1✉, Thierry Facon2, Saad Z. Usmani 3, Nizar Bahlis 4, Noopur Raje5, Torben Plesner6, Robert Z. Orlowski 7,
Supratik Basu 8, Hareth Nahi 9, Cyrille Hulin 10, Hang Quach 11, Hartmut Goldschmidt 12, Michael O’Dwyer 13,
Aurore Perrot 14, Christopher P. Venner15,16, Katja Weisel 17, Mourad Tiab18, Margaret Macro19, Laurent Frenzel20, Xavier Leleu 21,
George Wang22, Huiling Pei23, Maria Krevvata22, Robin Carson22, Fredrik Borgsten24 and Shaji K. Kumar
1Hematology Department, University Hospital Hôtel-Dieu, Nantes, France. 2University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France. 3Memorial Sloan Kettering
Cancer Center, New York, NY, USA. 4Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada. 5Center for Multiple Myeloma, Massachusetts
General Hospital Cancer Center, Boston, MA, USA. 6Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 7Department of Lymphoma & Myeloma, The University of
Texas MD Anderson Cancer Center, Houston, TX, USA. 8Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, UK.
9Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden. 10Department of Hematology, Hôpital
Haut Lévêque, University Hospital, Pessac, France. 11University of Melbourne, St Vincent’s Hospital, Melbourne, Australia. 12GMMG-Study Group at University Hospital Heidelberg,
Internal Medicine V, Heidelberg, Germany. 13Department of Medicine/Haematology, University of Galway, Galway, Republic of Ireland. 14CHU de Toulouse, IUCT-O, Université de
Toulouse, UPS, Service d’Hématologie, Toulouse, France. 15Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 16Department
of Medical Oncology, BC Cancer – Vancouver Centre, University of British Columbia, Vancouver, BC, Canada. 17Department of Oncology, Hematology and Bone Marrow
Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 18CHD Vendée, La Roche sur Yon, France. 19Centre Hospitalier
Universitaire (CHU) de Caen, Caen, France. 20Hôpital Necker-Enfants Malades, Paris, France. 21CHU Poitiers, Hôpital la Milétrie, Poitiers, France. 22Janssen Research & Development,
LLC, Spring House, PA, USA. 23Janssen Research & Development, LLC, Titusville, NJ, USA. 24Janssen Research & Development, LLC, Raritan, NJ, USA. 25Department of Hematology,
Mayo Clinic Rochester, Rochester, MN, USA.